NexCore Group Named 2023 Top Outpatient Healthcare Real Estate Developer

Posted April 25, 2023

NexCore Group has been named a 2023 Top Outpatient Healthcare Real Estate Developer by Revista's Outpatient Healthcare Real Estate Development survey. From January to December 2022, NexCore started or completed 10 developer-owned outpatient office buildings comprising 723,830 square feet. The total construction value for these projects totals $324.7 million.

The 2023 Outpatient Healthcare Real Estate Development Survey captured the number of medical office spaces and other outpatient real estate projects that either started or completed construction in 2022. These projects included MOBs, outpatient surgery centers, dialysis centers, clinics, freestanding emergency rooms/departments, imaging centers, urgent care centers, retail medical buildings, and other purpose-built facilities that delivered out-patient care.

This year's report contained voluntary data from 20 companies, along with derived data from an additional 180 companies, resulting in 200 total developers being included in the survey. Of the 200 developers who participated, NexCore Group ranked first for the number of developer-owned projects started or completed in 2022.

Todd Varney, Chief Development Officer and Managing Partner of NexCore Group, expressed he is thrilled that NexCore has again been recognized as the top healthcare real estate developer in the nation. "At NexCore, we strive to deliver innovative and collaborative healthcare real estate solutions that provide better outcomes for our clients and their communities," he said. "We are proud to be recognized as the national leader in healthcare real estate, and we are excited to continue developing high-quality outpatient facilities that meet current and future healthcare demands."

HREI magazine is featuring highlights from the survey in an upcoming edition. To read the cover story, please visit www.HREInsights.com.

The full report is available exclusively to Revista subscribers. Please contact Hilda Martin at 443-949-8794 or hilda@revistamed.com for more information or to subscribe.